Guy Rostoker
Research Subjects
Guy Rostoker has a total of 480 co-authors. Here are the top co-authors by number of shared publications:
Mireille Griuncelli
Ramsay Health Care, Claude Galien Private Hospital Department of Nephrology and Dialysis Quincy-sous-Sénart
20 shared publicationsG. Lagrue
Centre de tabacologie, hôpital Albert-Chenevier, Creteil, France
18 shared publicationsB. Weil
Departments of Nephrology, Bacteriology-Virology and Hepatology, Hôpital Henri Mondor 51 avenue du Maréchal de Lattre de Tassigny, 94010 Créteil, France
15 shared publicationsP Lang
15 shared publicationsYves Cohen
Ramsay Health Care, Claude Galien Private Hospital Department of Radiology Quincy-sous-Sénart
14 shared publicationsChristelle Loridon
Ramsay Health Care, Claude Galien Private Hospital Department of Nephrology and Dialysis Quincy-sous-Sénart
12 shared publications
Latest Publications
- Open Access
- 17 December 2025
- Published by Registre de Dialyse Peritoneale de Langue Francaise (RDPLF) in Bulletin de la Dialyse à Domicile
- Vol. 8 (4) , 295-298
Assisted peritoneal dialysis in France threatened by restrictive interpretation of legislation by CPAM?
France has been a pioneer in the implementation of assisted peritoneal dialysis (PD), with its first institutional programs launched in the late 1970s. According to data from the French-language Peritoneal Dialysis Registry (RDPLF), approximately a third of patients treated by PD receive assistance, placing France among the european and OECD countries with the highest proportion of assisted peritoneal dialysis. Assisted PD is recommended by european and international guidelines, which are based on the french model. A recent incident at the Bouchard Clinic in Marseille highlights the current administrative challenges associated with peritoneal dialysis assisted by private nurses. It also underscores the potential risks of a restrictive interpretation of administrative policies by certain primary health insurance funds. It is vital that the medical and cultural achievement of assisted peritoneal dialysis be defended. On October 6, 2025, the events in Marseille led stakeholders from the nephrology community, the nursing world, patient associations and hospital federations to write a joint letter of alert to the Director of Healthcare Provision at the French Ministry of Health on this issue.
- 17 December 2025
- Published by Registre de Dialyse Peritoneale de Langue Francaise (RDPLF) in Bulletin de la Dialyse à Domicile
- Vol. 8 (4) , 295-298
Open AccessAssisted peritoneal dialysis in France threatened by restrictive interpretation of legislation by CPAM?
France has been a pioneer in the implementation of assisted peritoneal dialysis (PD), with its first institutional programs launched in the late 1970s. According to data from the French-language Peritoneal Dialysis Registry (RDPLF), approximately a third of patients treated by PD receive assistance, placing France among the european and OECD countries with the highest proportion of assisted peritoneal dialysis. Assisted PD is recommended by european and international guidelines, which are based on the french model. A recent incident at the Bouchard Clinic in Marseille highlights the current administrative challenges associated with peritoneal dialysis assisted by private nurses. It also underscores the potential risks of a restrictive interpretation of administrative policies by certain primary health insurance funds. It is vital that the medical and cultural achievement of assisted peritoneal dialysis be defended. On October 6, 2025, the events in Marseille led stakeholders from the nephrology community, the nursing world, patient associations and hospital federations to write a joint letter of alert to the Director of Healthcare Provision at the French Ministry of Health on this issue.
- Open Access
- 6 October 2025
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 18 (11)
Evidence of pancreatic iron deposits and their association with mortality in dialysis-associated iatrogenic hemosiderosis
Background: Iron overload by liver magnetic resonance imaging (MRI) is highly prevalent today in the hemodialysis population worldwide and is a controversial topic in the management of dialysis-related anemia, as iron deposits can be seen on MRI but without clinical consequences. The aim of this study was to look for evidence of pancreatic iron deposits (a surrogate marker of severity in iron overload diseases) and their possible association with mortality. Methods: Liver iron concentration was analyzed in 115 patients on dialysis using signal intensity ratio MRI and R2* Relaxometry MRI to determine liver, spleen, spine and pancreas iron loads. Results: Overall, 44.3% (51/115) had liver iron overload upon MRI and 20% (23/115) of patients exhibited increased pancreatic iron load. The percentage of patients with abnormal pancreatic T2* was significantly higher in the group with moderate and severe liver iron overload [46.7% (7/15)] as compared with the groups of patients with normal iron load [15.6% (10/64)] and mild iron overload [16.7% (6/36)] (P = .032, Fisher’s exact test). Median survival time was reduced to 2.6 years in patients with pancreatic iron deposits as compared with 6.6 years in patients with normal pancreatic iron (P = .028, Log-rank test). Pancreatic iron deposits were associated with a 3-fold higher risk of death in the Cox proportional hazard regression model (hazard ratio 3.614, P = .0031). Conclusion: Pancreatic iron deposits are observed in a substantial proportion of patients on dialysis with moderate and severe liver iron overload and may be associated with an increased risk of mortality. Trial registration: ClinicalTrials.gov number NCT05593068.
- 6 October 2025
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 18 (11)
Open AccessEvidence of pancreatic iron deposits and their association with mortality in dialysis-associated iatrogenic hemosiderosis
Background: Iron overload by liver magnetic resonance imaging (MRI) is highly prevalent today in the hemodialysis population worldwide and is a controversial topic in the management of dialysis-related anemia, as iron deposits can be seen on MRI but without clinical consequences. The aim of this study was to look for evidence of pancreatic iron deposits (a surrogate marker of severity in iron overload diseases) and their possible association with mortality. Methods: Liver iron concentration was analyzed in 115 patients on dialysis using signal intensity ratio MRI and R2* Relaxometry MRI to determine liver, spleen, spine and pancreas iron loads. Results: Overall, 44.3% (51/115) had liver iron overload upon MRI and 20% (23/115) of patients exhibited increased pancreatic iron load. The percentage of patients with abnormal pancreatic T2* was significantly higher in the group with moderate and severe liver iron overload [46.7% (7/15)] as compared with the groups of patients with normal iron load [15.6% (10/64)] and mild iron overload [16.7% (6/36)] (P = .032, Fisher’s exact test). Median survival time was reduced to 2.6 years in patients with pancreatic iron deposits as compared with 6.6 years in patients with normal pancreatic iron (P = .028, Log-rank test). Pancreatic iron deposits were associated with a 3-fold higher risk of death in the Cox proportional hazard regression model (hazard ratio 3.614, P = .0031). Conclusion: Pancreatic iron deposits are observed in a substantial proportion of patients on dialysis with moderate and severe liver iron overload and may be associated with an increased risk of mortality. Trial registration: ClinicalTrials.gov number NCT05593068.
- Open Access
Serological Correlate of Protection Established by Neutralizing Antibodies Differs Among Dialysis Patients with SARS-CoV-2 Variants of Concern
Background: The 2019 coronavirus disease (COVID-19) pandemic had a severe impact on frail, end-stage kidney disease (ESKD) patients, either on dialysis or transplanted, with a high mortality rate in the early waves. Vaccination against SARS-CoV-2 with mRNA vaccines has led to reduced hospitalization and mortality rates in the general population and ESKD patients. Neutralizing antibodies (NAbs) are a valuable correlate of protection after vaccination, and IgG anti-spike antibodies are considered a surrogate marker of protection. Methods: This study investigated the correlates of protection brought by NAb and anti-spike IgG antibodies against SARS-CoV-2 wild-type Wuhan strain and variants of concern in a cohort of 128 French patients on dialysis after vaccination with the BNT162b2 mRNA vaccine. The correlate was assessed using Receiver Operating Characteristic curves. Results: The level of protection for IgG anti-spike antibodies was set at 917 BAU/mL for the original Wuhan strain and 980 BAU/mL and 1450 BAU/mL, respectively, for the Delta and Omicron BA.1 variants. Conclusions: The level of protection can be regularly monitored by measuring IgG anti-spike antibody concentrations to allow tailored boosters of SARS-CoV-2 vaccination in this frail and immunocompromised ESKD population.
Open AccessSerological Correlate of Protection Established by Neutralizing Antibodies Differs Among Dialysis Patients with SARS-CoV-2 Variants of Concern
Background: The 2019 coronavirus disease (COVID-19) pandemic had a severe impact on frail, end-stage kidney disease (ESKD) patients, either on dialysis or transplanted, with a high mortality rate in the early waves. Vaccination against SARS-CoV-2 with mRNA vaccines has led to reduced hospitalization and mortality rates in the general population and ESKD patients. Neutralizing antibodies (NAbs) are a valuable correlate of protection after vaccination, and IgG anti-spike antibodies are considered a surrogate marker of protection. Methods: This study investigated the correlates of protection brought by NAb and anti-spike IgG antibodies against SARS-CoV-2 wild-type Wuhan strain and variants of concern in a cohort of 128 French patients on dialysis after vaccination with the BNT162b2 mRNA vaccine. The correlate was assessed using Receiver Operating Characteristic curves. Results: The level of protection for IgG anti-spike antibodies was set at 917 BAU/mL for the original Wuhan strain and 980 BAU/mL and 1450 BAU/mL, respectively, for the Delta and Omicron BA.1 variants. Conclusions: The level of protection can be regularly monitored by measuring IgG anti-spike antibody concentrations to allow tailored boosters of SARS-CoV-2 vaccination in this frail and immunocompromised ESKD population.
- Open Access
- 2 May 2025
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 137, 73-82
Cost-effectiveness of daily home haemodialysis versus in-centre haemodialysis: A propensity score matching analysis based on real-world data from the French healthcare system
- 2 May 2025
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 137, 73-82
Open AccessCost-effectiveness of daily home haemodialysis versus in-centre haemodialysis: A propensity score matching analysis based on real-world data from the French healthcare system
- Open Access
- 20 December 2024
- Published by Oxford University Press (OUP) in Journal Of Nephrology
- Vol. 38 (1) , 301-304
mRNA vaccine against SARS-CoV-2 response is comparable between patients on dialysis and healthy controls after adjustment for age, gender and history of COVID-19 infection
- 20 December 2024
- Published by Oxford University Press (OUP) in Journal Of Nephrology
- Vol. 38 (1) , 301-304
Open AccessmRNA vaccine against SARS-CoV-2 response is comparable between patients on dialysis and healthy controls after adjustment for age, gender and history of COVID-19 infection
- Open Access
Clustering Analysis Identified Distinct Clinical Phenotypes among Hemodialysis Patients in Their Immunological Response to the BNT162b2 mRNA Vaccine against SARS-CoV-2
Background: The 2019 coronavirus disease (COVID-19) pandemic induced a major health crisis worldwide, notably among end-stage kidney disease (ESKD) patients. Vaccination against SARS-CoV-2, especially with messenger RNA (mRNA) vaccines, is highly effective and reduces hospitalization and mortality in both the general and ESKD populations. Age and previous COVID-19 infection have been identified as major determinants of the vaccine response in both the general population and ESKD patients. Methods: To determine the specific phenotype of ESKD patients in relation to their vaccine response, a clustering approach was used in a cohort of 117 fully vaccinated patients. Results: Clustering revealed three distinct clinical phenotypes among hemodialysis patients in terms of immunological response. Two clusters, consisting of either women with a long dialysis history or male subjects with diabetes with a moderate history of dialysis, exhibited low levels of IgG anti-spike antibodies. The third cluster consisted of non-diabetic middle-aged men with a moderate dialysis vintage and a very good serological response to vaccination. Conclusions: These vaccinal phenotypes of dialysis patients are easily identifiable in current practice, allowing for differential serological follow-up and tailored booster SARS-CoV-2 vaccination.
Open AccessClustering Analysis Identified Distinct Clinical Phenotypes among Hemodialysis Patients in Their Immunological Response to the BNT162b2 mRNA Vaccine against SARS-CoV-2
Background: The 2019 coronavirus disease (COVID-19) pandemic induced a major health crisis worldwide, notably among end-stage kidney disease (ESKD) patients. Vaccination against SARS-CoV-2, especially with messenger RNA (mRNA) vaccines, is highly effective and reduces hospitalization and mortality in both the general and ESKD populations. Age and previous COVID-19 infection have been identified as major determinants of the vaccine response in both the general population and ESKD patients. Methods: To determine the specific phenotype of ESKD patients in relation to their vaccine response, a clustering approach was used in a cohort of 117 fully vaccinated patients. Results: Clustering revealed three distinct clinical phenotypes among hemodialysis patients in terms of immunological response. Two clusters, consisting of either women with a long dialysis history or male subjects with diabetes with a moderate history of dialysis, exhibited low levels of IgG anti-spike antibodies. The third cluster consisted of non-diabetic middle-aged men with a moderate dialysis vintage and a very good serological response to vaccination. Conclusions: These vaccinal phenotypes of dialysis patients are easily identifiable in current practice, allowing for differential serological follow-up and tailored booster SARS-CoV-2 vaccination.
- Open Access
- 3 June 2024
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 17 (7) , sfae162
Dialysis nurse demand in Europe: an estimated prediction based on modelling
Background: To estimate the projections of supply and demand for dialysis nurses (DNs) over 5 years in four European countries (France, Italy, Spain and the UK). Methods: This study modelled the nursing labour workforce across each jurisdiction by estimating the current nursing labour force, number of nursing graduates and the attrition rate. Results: France currently has the greatest demand for DNs (51 325 patients on dialysis), followed by Italy, the UK and Spain with 40 661, 30 301 and 28 007 patients on dialysis, respectively. The number of in-centre haemodialysis (HD) patients is expected to increase in the four countries, while the number of patients on home HD (HHD) or on peritoneal dialysis (PD) is expected to increase in the UK. Currently Italy has the greatest proportion of DNs (2.6%), followed by France (2.1%), Spain (1.7%) and the UK (1.5%). Estimation of the dialysis nursing staff growth rate over 5 years showed that the UK has the greatest estimated growth rate (6%), followed by Italy (2%), France (2%) and Spain (1%). Conclusions: Dialysis demand will increase in the coming years, which may exacerbate the DN shortage. Additionally, competencies and training requirements of DNs should be precisely defined. Finally, implementing and facilitating PD and HHD strategies would be helpful for patients, healthcare professionals and healthcare systems and can even help ease the DN shortage.
- 3 June 2024
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 17 (7) , sfae162
Open AccessDialysis nurse demand in Europe: an estimated prediction based on modelling
Background: To estimate the projections of supply and demand for dialysis nurses (DNs) over 5 years in four European countries (France, Italy, Spain and the UK). Methods: This study modelled the nursing labour workforce across each jurisdiction by estimating the current nursing labour force, number of nursing graduates and the attrition rate. Results: France currently has the greatest demand for DNs (51 325 patients on dialysis), followed by Italy, the UK and Spain with 40 661, 30 301 and 28 007 patients on dialysis, respectively. The number of in-centre haemodialysis (HD) patients is expected to increase in the four countries, while the number of patients on home HD (HHD) or on peritoneal dialysis (PD) is expected to increase in the UK. Currently Italy has the greatest proportion of DNs (2.6%), followed by France (2.1%), Spain (1.7%) and the UK (1.5%). Estimation of the dialysis nursing staff growth rate over 5 years showed that the UK has the greatest estimated growth rate (6%), followed by Italy (2%), France (2%) and Spain (1%). Conclusions: Dialysis demand will increase in the coming years, which may exacerbate the DN shortage. Additionally, competencies and training requirements of DNs should be precisely defined. Finally, implementing and facilitating PD and HHD strategies would be helpful for patients, healthcare professionals and healthcare systems and can even help ease the DN shortage.
- 23 January 2024
- Published by Oxford University Press (OUP) in Journal Of Nephrology
- Vol. 37 (2) , 451-459
Epidemiology of tobacco use in dialysis patients in France and survey of nephrologists’ involvement in counseling on tobacco discontinuation
Background Tobacco smoking is an independent risk factor for chronic kidney disease (CKD) and increases morbidity and mortality in CKD patients. The primary objective of the study was to investigate the epidemiology of smoking in patients undergoing maintenance dialysis in France. A second objective was to assess the involvement of nephrologists in supporting patients for smoking cessation. Methods Data on the smoking history of prevalent patients on maintenance dialysis in France between 2010 and 2020 were obtained from the REIN database (Renal Epidemiology and Information Network), updated by all French nephrology and dialysis centers. As for the support to smoking discontinuation, a questionnaire on smoking cessation assistance was sent to all members of the French Society of Nephrology, Dialysis and Transplantation (SFNDT). Results The proportion of current smokers among patients on maintenance dialysis was 10.4% in 2010, 11.2% in 2015 and 11.6% in 2020. A total of 228 nephrologists among the 790 members of the SFNDT participated in the survey (28.9%). Most respondents were women (57.3%), worked at a public hospital (61.1%), were under 40 years of age (51.3%) and had no history of smoking (60.8%). The majority reported asking patients about their smoking status and offering brief advice. Among respondents, 72.8% offered help with smoking cessation, 46.3% referred their smoking patients to a tobacco specialist, 51.8% reported prescribing drugs to quit tobacco, and 81.6% requested further training in how to support patients for smoking cessation. Conclusion Smoking cessation training for nephrologists and dedicated programs for patients in nephrology units could improve our practices and decrease the high prevalence of smoking in patients with ESKD. Graphical Abstract
- 23 January 2024
- Published by Oxford University Press (OUP) in Journal Of Nephrology
- Vol. 37 (2) , 451-459
Epidemiology of tobacco use in dialysis patients in France and survey of nephrologists’ involvement in counseling on tobacco discontinuation
Background Tobacco smoking is an independent risk factor for chronic kidney disease (CKD) and increases morbidity and mortality in CKD patients. The primary objective of the study was to investigate the epidemiology of smoking in patients undergoing maintenance dialysis in France. A second objective was to assess the involvement of nephrologists in supporting patients for smoking cessation. Methods Data on the smoking history of prevalent patients on maintenance dialysis in France between 2010 and 2020 were obtained from the REIN database (Renal Epidemiology and Information Network), updated by all French nephrology and dialysis centers. As for the support to smoking discontinuation, a questionnaire on smoking cessation assistance was sent to all members of the French Society of Nephrology, Dialysis and Transplantation (SFNDT). Results The proportion of current smokers among patients on maintenance dialysis was 10.4% in 2010, 11.2% in 2015 and 11.6% in 2020. A total of 228 nephrologists among the 790 members of the SFNDT participated in the survey (28.9%). Most respondents were women (57.3%), worked at a public hospital (61.1%), were under 40 years of age (51.3%) and had no history of smoking (60.8%). The majority reported asking patients about their smoking status and offering brief advice. Among respondents, 72.8% offered help with smoking cessation, 46.3% referred their smoking patients to a tobacco specialist, 51.8% reported prescribing drugs to quit tobacco, and 81.6% requested further training in how to support patients for smoking cessation. Conclusion Smoking cessation training for nephrologists and dedicated programs for patients in nephrology units could improve our practices and decrease the high prevalence of smoking in patients with ESKD. Graphical Abstract
- Open Access
- 19 January 2024
- Published by Elsevier in Kidney International Reports
- Vol. 9 (4) , 1119-1121
Contrasting Evolution After Withdrawal of Long-Term Administration of Difelikefalin for CKD-Associated Pruritus
- 19 January 2024
- Published by Elsevier in Kidney International Reports
- Vol. 9 (4) , 1119-1121
Open AccessContrasting Evolution After Withdrawal of Long-Term Administration of Difelikefalin for CKD-Associated Pruritus